

MARKET REPORT



Thalassemia - Pipeline Review, H1 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Thalassemia - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Thalassemia - Pipeline Review, H1 2017

Thalassemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9080IDB

Number of Pages : 140

Report Format : PDF

Publisher Information :

Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Thalassemia - Pipeline Review, H1 2017

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageThalassemia - OverviewThalassemia - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesThalassemia - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeThalassemia - Companies Involved in Therapeutics DevelopmentAcceleron Pharma IncAgiros Pharmaceuticals IncAlnylam Pharmaceuticals Incbluebird bio IncCalimmune IncCRISPR TherapeuticsEditas Medicine IncErrant Gene Therapeutics LLCGamida Cell LtdGilead Sciences IncIncyte CorpIonis Pharmaceuticals IncIRBM Science Park SpAJohnson & JohnsonKiadis Pharma NVLa Jolla Pharmaceutical CompanyMerck & Co IncPharmaEssentia CorpProtagonist Therapeutics IncSangamo Therapeutics IncZyduz Cadila Healthcare LtdThalassemia - Drug Profiles(decitabine + tetrahydrouridine) - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressACY-957 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAG-348 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressALN-TMP - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressambriesentan - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressATIR-201 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBB-305 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbenserazide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCAL-H - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCNTO-530 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCordIn - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDrugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGene Therapy for Sickle Cell Disease and Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGSK-2696277 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIMR-687 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIONISTMPRSS-6LRx - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressLJPC-401 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressluspatercept - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressM-009 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressM-012 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNiCord - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPEG-EPO - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPHBB-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPTG-300 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRCY-1497 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressruxolitinib phosphate - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSCD-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresssirolimus - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressssotatercept - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Beta Thalassemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressThalagen - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressThalassemia - Dormant ProjectsThalassemia - Product Development MilestonesFeatured News & Press ReleasesFeb 06, 2017: Kiadis Pharma Provides Update on ATIR201Dec 15, 2016: Kiadis Pharma announces initiation of Phase I/II clinical trial with ATIR201 for thalassemiaDec 14, 2016: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β -ThalassemiaDec 06, 2016: bluebird bio Provides Updates on HSC Gene Therapy ProgramsDec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual

Meeting of the American Society of Hematology Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HGB) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia Dec 03, 2016: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent β -Thalassemia and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Dec 02, 2016: Acetylon to present data on ACY-957 at the American Society of Hematology Annual Meeting Nov 21, 2016: CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β -Thalassemia Nov 03, 2016: bluebird bio to Present New Data from Three LentiGlobin Clinical Studies at American Society of Hematology (ASH) Annual Meeting Oct 13, 2016: bluebird bio Provides Update on LentiGlobin Programs and Research and Development Strategy at Gene Therapy Day Sep 21, 2016: LentiGlobin Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program Sep 08, 2016: bluebird bio Opens Phase 3 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia Sep 07, 2016: La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

How to Buy...

Thalassemia - Pipeline Review, H1 2017

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/50192>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1700** | Single User Price
- \$3400** | Site License Price
- \$5100** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.